Mesoblast Ltd ADR (MESO)

[biocqr]

Interim Results From Mesoblast's Phase 2 Heart Failure Trial Shows 'Off-The-Shelf' Proprietary Adult Stem Cell Product Revascor Reduces Cardiac Events, Mortality, and Hospitalization

>Analyses of time-dependent hard efficacy endpoints showed that a single injection of Revascor™ significantly reduced the number of patients who developed any severe adverse cardiac events over the follow-up period from 93.3% in the control group to 44.4% in the treated patients (p=0.001). Revascor™ also significantly reduced the number of patients who developed any major adverse cardiac events (MACE, defined as the composite of cardiac death, heart attack, or coronary revascularization procedures) from 40% to 6.7% (p=0.005). A single injection of Revascor™ reduced the overall monthly event rate of a MACE by 84% compared with controls (p=0.01), and every dose tested demonstrated a similar protective effect. Death from cardiac causes was reduced from 13.3% to 0% over this period (p=0.059) and the overall monthly rate of cardiac-related hospitalizations was reduced by 48% (p=0.07). <

http://finance.yahoo.com/news/Interim-Results-From-prnews-3122195240.html?x=0&.v=1


Wow - a single injection reduced monthly MACE rate by 84%. Zero deaths in the treated group vs. 13.3% in the control group. This will become the gold standard treatment for heart failure.